<DOC>
	<DOCNO>NCT01062971</DOCNO>
	<brief_summary>To compare intraocular pressure lower effectiveness new fix combination drug .</brief_summary>
	<brief_title>Clinical Study A Fixed Combination Timolol-Brimonidine-Dorzolamide</brief_title>
	<detailed_description>This multicentric , double blind prospective clinical study . We include patient confirm diagnosis primary open-angle glaucoma and/or ocular hypertension , intraocular pressure ( IOP ) range 21 31 mm Hg . Patients randomly divide 2 group , one treat new formulation 0.5 % timolol-0.2 % brimonidine-2 % dorzolamide fix combination ( Krytantek Ofteno® , Laboratorios Sophia , Mexico ) one treat 0.5 % timolol-2 % dorzolamide fix combination ( Cosopt® , MSD Laboratories , USA ) . Patients receive 1 drop twice day either formulation examine day 2 , 7 , 15 , 30 , 60 , 90 initiation treatment . The primary objective compare efficacy formulation , estimate decrease IOP . A Goldmann applanation tonometer use IOP determination .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Dorzolamide</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<criteria>Adult subject either sex race openangle glaucoma ocular hypertension ; Visual acuity 20/40 20/80 better ( Snellen equivalent ) . Clinically relevant ophthalmic systemic condition may exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Open-angle glaucoma</keyword>
	<keyword>Ocular hypertension</keyword>
	<keyword>POAG</keyword>
</DOC>